Calcium Electroporation for the Treatment of Colorectal Cancer

Phase 1

Completed

• Conditions: Colorectal Cancer Stage IV
• Interventions: Combination Product: Calcium electroporation

• Registration Number: NCT03542214
• Lead Sponsor: Zealand University Hospital

Brief Summary

In this phase I study 6 patients with inoperable colorectal cancer is treated with calcium electroporation to establish safety and efficacy of the treatment.

Detailed Description

A total of 6 evaluable patients with inoperable colorectal cancer are expected to be included in the study and the time for inclusion of patients is estimated to be 1-2 years. All patients will have been offered the standard of care and all available alternatives before entering the protocol. Calcium electroporation will not be compared to other means of treatment.

All patients will be treated once, but in case of residual tumor tissue at follow-up, and if the investigator considers it safe, they will be offered re-treatment. A maximum of 3 treatments per patient will be conducted with an interval of minimum 4 weeks. The patients will be followed with regular examinations for 12 months, starting from first treatment day.

Study Timeline

• Study First Submitted: 2018-01-29
• Study Start: 2018-04-24
• Study First Submitted QC: 2018-05-30
• Study First Posted: 2018-05-31
• Primary Completion: 2020-10-01
• Study Completion: 2021-01-01
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-24
• Last Update Posted: 2021-02-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Histologically verified colorectal tumor
• Conferred by multidisciplinary team (radiologists, surgeons and oncologists) discussing options possible for the patient, resulting in agreement that an endoscopic treatment with calcium electroporation should be offered to the patient.
• Treatment free interval of minimum 2 weeks.
• Thrombocytes ≥ 50 billions/l, INR >1,2. Medical correction is allowed, e.g. correction of elevated INR by means of vitamin K.
• Performance status ECOG/WHO ≤2
• Both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch.)
• Trial subject ≥ 18 years.
• Trial subject must be able to understand the participants' information.
• Signed informed consent. The patients are considered participants in the study after signing of the informed consent.

Exclusion criteria:

• Coagulative disturbance that cannot be corrected
• Pregnancy or lactation (Pregnancy is ruled out in fertile women by an HCG test in a blood sample)
• Concurrent participation in other clinical trials that involve experimental drugs or participation in a clinical trial involving experimental drugs within 4 weeks prior to administration of the drug in this study.
• Treatment with bevacizumab within the last 4 weeks.
• Heavily inflamed colorectal mucus membrane with bleeding or ulcerations.
• Implanted colon stent
• Other clinical disease or previous treatments that make the investigator deem the patient unfit.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Calcium electroporation treatment	Calcium electroporation	Experimental treatment with calcium electroporation for inoperabel colorectal cancer

Primary Outcome Measures

Name	Time	Method
Safety of the calcium electroporation procedure in colorectal cancer (registration of adverse events; CTCAE v4 will be used)	12 months	Safety will be assessed through registration of adverse events related to the treatment. Furthermore, CT scans and follow-up endoscopies are performed as a safety marker to exclude any perforations, bleeding or infections. CTCAE v4 will be used.

Secondary Outcome Measures

Name	Time	Method
Local response	18 months	Tumor biopsies will be analyzed regarding standard histology and immunologic infiltration (CD8/CD3 and PD-L1/PD1)
Systemic respons to calcium electroporation in colorectal cancer.	12 months	Blood samples will be collected. Multiplex cytokine analyses and transcriptional analyses will be performed. Furthermore cell adhesion assay will be performed. Additionally circulating tumor DNA will be measured as a marker for the tumor burden
Tumorregression	12 months	CT/MR scans are performed and analyzed according to RECIST-criteria

Trial Locations

Locations (1)

Zealand University Hospital; 🇩🇰 Roskilde, Denmark